Mechanistic insights toward dissociating therapeutic from psychedelic effects: bridging the gap between psychedelic research and mental health care.

Wykaz prac cytowanych wewnątrz artykułu (relacja cites → Publication), pobrany ze zweryfikowanych metadanych PubMed / Crossref:

1. Inserra A, De Gregorio D, Gobbi G. Psychedelics in psychiatry: neuroplastic, immunomodulatory, and neurotransmitter mechanisms. Pharmacol Rev. 2021;73:202–77.
   pubmed_reference_list
2. Vollenweider FX, Preller KH. Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders. Nat Rev Neurosci. 2020;21:611–24.
   pubmed_reference_list
3. Nichols DE. Psychedelics. Pharmacol Rev. 2016;68:264–355.
   pubmed_reference_list
4. Davis AK, Barrett FS, Griffiths RR. Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. J Contextual Behav Sci. 2020;15:39–45.
   pubmed_reference_list
5. Griffiths RR, Richards WA, Johnson MW, McCann UD, Jesse R. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol. 2008;22:621–32.
   pubmed_reference_list
6. Romeo B, Kervadec E, Fauvel B, Strika-Bruneau L, Amirouche A, Bezo A, et al. The intensity of the psychedelic experience is reliably associated with clinical improvements: A systematic review and meta-analysis. Neurosci Biobehav Rev. 2025;172:106086.
   pubmed_reference_list
7. Haijen EC, Kaelen M, Roseman L, Timmermann C, Kettner H, Russ S, et al. Predicting responses to psychedelics: a prospective study. Front Pharmacol. 2018;9:897.
   pubmed_reference_list
8. Roseman L, Nutt DJ, Carhart-Harris RL. Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front Pharmacol. 2018;8:974.
   pubmed_reference_list
9. Yaden DB, Griffiths RR. The subjective effects of psychedelics are necessary for their enduring therapeutic effects. ACS Pharmacol Transl Sci. 2020;4:568–72.
   pubmed_reference_list
10. Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Bäbler A, Vogel H, Hell D. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport. 1998;9:3897–902.
    pubmed_reference_list
11. Kometer M, Schmidt A, Jäncke L, Vollenweider FX. Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations. J Neurosci. 2013;33:10544–51.
    pubmed_reference_list
12. Quednow BB, Kometer M, Geyer MA, Vollenweider FX. Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers. Neuropsychopharmacology. 2012;37:630–40.
    pubmed_reference_list
13. Barrett FS, Preller KH, Herdener M, Janata P, Vollenweider FX. Serotonin 2A receptor signaling underlies LSD-induced alteration of the neural response to dynamic changes in music. Cereb Cortex. 2018;28:3939–50.
    pubmed_reference_list
14. Holze F, Avedisian I, Varghese N, Eckert A, Liechti ME. Role of the 5-HT(2A) receptor in acute effects of LSD on empathy and circulating oxytocin. Front Pharmacol. 2021;12:711255.
    pubmed_reference_list
15. Kraehenmann R, Pokorny D, Aicher H, Preller KH, Pokorny T, Bosch OG, et al. LSD increases primary process thinking via serotonin 2A receptor activation. Front Pharmacol. 2017;8:814.
    pubmed_reference_list
16. Kraehenmann R, Pokorny D, Vollenweider L, Preller KH, Pokorny T, Seifritz E, et al. Dreamlike effects of LSD on waking imagery in humans depend on serotonin 2A receptor activation. Psychopharmacology (Berl). 2017;234:2031–46.
    pubmed_reference_list
17. Olbrich S, Preller KH, Vollenweider FX. LSD and ketanserin and their impact on the human autonomic nervous system. Psychophysiology. 2021;58:e13822.
    pubmed_reference_list
18. Preller KH, Herdener M, Pokorny T, Planzer A, Kraehenmann R, Stämpfli P, et al. The fabric of meaning and subjective effects in LSD-Induced states depend on serotonin 2A receptor activation. Curr Biol. 2017;27:451–7.
    pubmed_reference_list
19. Preller KH, Burt JB, Ji JL, Schleifer CH, Adkinson BD, Stämpfli P, et al. Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor. eLife. 2018;7:e35082.
    pubmed_reference_list
20. Valle M, Maqueda AE, Rabella M, Rodríguez-Pujadas A, Antonijoan RM, Romero S, et al. Inhibition of alpha oscillations through serotonin-2A receptor activation underlies the visual effects of ayahuasca in humans. Eur Neuropsychopharmacol. 2016;26:1161–75.
    pubmed_reference_list
21. Carter OL, Burr DC, Pettigrew JD, Wallis GM, Hasler F, Vollenweider FX. Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors. J Cogn Neurosci. 2005;17:1497–508.
    pubmed_reference_list
22. Becker AM, Klaiber A, Holze F, Istampoulouoglou I, Duthaler U, Varghese N, et al. Ketanserin reverses the acute response to LSD in a randomized, double-blind, placebo-controlled, crossover study in healthy participants. Int J Neuropsychopharmacol. 2023;26:97–106.
    pubmed_reference_list
23. Sloshower J, Zeifman RJ, Guss J, Krause R, Safi-Aghdam H, Pathania S, et al. Psychological flexibility as a mechanism of change in psilocybin-assisted therapy for major depression: results from an exploratory placebo-controlled trial. Sci Rep. 2024;14:8833.
    pubmed_reference_list
24. Gukasyan N, Davis AK, Barrett FS, Cosimano MP, Sepeda ND, Johnson MW, et al. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. J Psychopharmacol. 2022;36:151–8.
    pubmed_reference_list
25. Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry. 2021;78:481–9.
    pubmed_reference_list
26. Pokorny T, Preller KH, Kraehenmann R, Vollenweider FX. Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience. Eur Neuropsychopharmacol. 2016;26:756–66.
    pubmed_reference_list
27. Rosenblat JD, Leon-Carlyle M, Ali S, Husain MI, McIntyre RS Antidepressant effects of psilocybin in the absence of psychedelic effects. Am J Psychiatry. 2023:appi.ajp.20220835.
    pubmed_reference_list
28. Maj J, Palider W, Rawłów A. Trazodone, a central serotonin antagonist and agonist. J Neural Transm. 1979;44:237–48.
    pubmed_reference_list
29. Ghanbari R, El Mansari M, Blier P. Sustained administration of trazodone enhances serotonergic neurotransmission: in vivo electrophysiological study in the rat brain. J Pharmacol Exp Ther. 2010;335:197–206.
    pubmed_reference_list
30. Pazzagli M, Giovannini MG, Pepeu G. Trazodone increases extracellular serotonin levels in the frontal cortex of rats. Eur J Pharmacol. 1999;383:249–57.
    pubmed_reference_list
31. Husain MI, Blumberger DM, Castle DJ, Ledwos N, Fellows E, Jones BD, et al. Psilocybin for treatment-resistant depression without psychedelic effects: study protocol for a 4-week, double-blind, proof-of-concept randomised controlled trial. BJPsych Open. 2023;9:e134.
    pubmed_reference_list
32. Fernández-Borkel T, Borkel LF, Rojas-Hernández J, Hernández-Álvarez E, Quintana-Hernández DJ, Ponti LG, et al. The causal role of consciousness in psychedelic therapy for treatment-resistant depression: hypothesis and proposal. ACS Pharmacol Transl Sci. 2025;8:2839–47.
    pubmed_reference_list
33. Lii TR, Smith AE, Flohr JR, Okada RL, Nyongesa CA, Cianfichi LJ, et al. Randomized trial of ketamine masked by surgical anesthesia in patients with depression. Nat Ment Health. 2023;1:876–86.
    pubmed_reference_list
34. O’Connor S, Godfrey K, Reed S, Peill J, Rohani-Shukla C, Healy M, et al. Study Protocol for ‘PsilOCD: A Pharmacological Challenge Study Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity. Cureus. 2025;17:e78171.
    pubmed_reference_list
35. Cybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose [press release]. Toronto (ON), Canada 2023.
    pubmed_reference_list
36. Canady VA. FDA gives breakthrough designation for psychedelic treatment. Mental Health Weekly. 2024;34:7–8.
    pubmed_reference_list
37. Ippolito A, Vasudevan S, Hurley S, Gilmour G, Westhorpe F, Churchill G, et al. Evidence that 5-HT2A receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non-psychedelic drugs. Br J Pharmacol. 2025.
    pubmed_reference_list
38. Hougaku H, Matsumoto M, Hata R, Handa N, Imaizumi M, Sugitani Y, et al. Therapeutic effect of lisuride maleate on post-stroke depression. Nihon Ronen Igakkai Zasshi. 1994;31:52–9.
    pubmed_reference_list
39. González-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, et al. Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. Neuron. 2007;53:439–52.
    pubmed_reference_list
40. Ekins TG, Rybicki-Kler C, Deng T, Brooks IAW, Jedrasiak-Cape I, Donoho E, et al. Psychedelic neuroplasticity of cortical neurons lacking 5-HT2A receptors. Mol Psychiatry. 2025.
    pubmed_reference_list
41. Shao L-X, Liao C, Gregg I, Davoudian PA, Savalia NK, Delagarza K, et al. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron. 2021;109:2535–44.e4.
    pubmed_reference_list
42. Hesselgrave N, Troppoli TA, Wulff AB, Cole AB, Thompson SM. Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. Proc Natl Acad Sci. 2021;118:e2022489118.
    pubmed_reference_list
43. Sekssaoui M, Bockaert J, Marin P, Bécamel C. Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT2A receptor the unique player?. Neuropsychopharmacology. 2024;49:747–56.
    pubmed_reference_list
44. Aarrestad IK, Cameron LP, Fenton EM, Casey AB, Rijsketic DR, Patel SD, et al. The psychoplastogen tabernanthalog induces neuroplasticity without proximate immediate early gene activation. Nat Neurosci. 2025;28:1919–31.
    pubmed_reference_list
45. Morales-Garcia JA, Calleja-Conde J, Lopez-Moreno JA, Alonso-Gil S, Sanz-SanCristobal M, Riba J, et al. N,N-dimethyltryptamine compound found in the hallucinogenic tea ayahuasca, regulates adult neurogenesis in vitro and in vivo. Transl Psychiatry. 2020;10:331.
    pubmed_reference_list
46. Moliner R, Girych M, Brunello CA, Kovaleva V, Biojone C, Enkavi G, et al. Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. Nat Neurosci. 2023;26:1032–41.
    pubmed_reference_list
47. Jaster AM, Hadlock TM, Buzzi B, Maltman JL, Silva GM, Saha S, et al. Sex-specific role of the 5-HT2A receptor in psilocybin-induced extinction of opioid reward. Nat Commun. 2025;16:10206.
    pubmed_reference_list
48. Floris G, Dabrowski KR, Zanda MT, Daws SE. Psilocybin reduces heroin seeking behavior and modulates inflammatory gene expression in the nucleus accumbens and prefrontal cortex of male rats. Mol Psychiatry. 2025;30:1801–16.
    pubmed_reference_list
49. de la Fuente Revenga M, Zhu B, Guevara CA, Naler LB, Saunders JM, Zhou Z, et al. Prolonged epigenomic and synaptic plasticity alterations following single exposure to a psychedelic in mice. Cell Rep. 2021;37:109836.
    pubmed_reference_list
50. Schmitz GP, Chiu Y-T, Foglesong ML, Magee SN, MacKinnon M, König GM, et al. Psychedelic compounds directly excite 5-HT2A layer V medial prefrontal cortex neurons through 5-HT2A Gq activation. Transl Psychiatry. 2025;15:381.
    pubmed_reference_list
51. Cao D, Yu J, Wang H, Luo Z, Liu X, He L, et al. Structure-based discovery of nonhallucinogenic psychedelic analogs. Science. 2022;375:403–11.
    pubmed_reference_list
52. Dong C, Ly C, Dunlap LE, Vargas MV, Sun J, Hwang IW, et al. Psychedelic-inspired drug discovery using an engineered biosensor. Cell. 2021;184:2779–92.e18.
    pubmed_reference_list
53. Lewis V, Bonniwell EM, Lanham JK, Ghaffari A, Sheshbaradaran H, Cao AB, et al. A non-hallucinogenic LSD analog with therapeutic potential for mood disorders. Cell Rep. 2023;42:112203.
    pubmed_reference_list
54. Tuck JR, Dunlap LE, Khatib YA, Hatzipantelis CJ, Weiser Novak S, Rahn RM, et al. Molecular design of a therapeutic LSD analogue with reduced hallucinogenic potential. Proc Natl Acad Sci. 2025;122:e2416106122.
    pubmed_reference_list
55. Puigseslloses P, Nadal-Gratacós N, Fumàs B, Modenutti CP, Pottie E, Ortigosa JR, et al. Neuropharmacology of halogenated DMT analogs: psychoplastogenic and antidepressant properties of 5-Br-DMT, a psychedelic derivative with low hallucinogenic potential. Mol Psychiatry. 2026;31:1733–1745.
    pubmed_reference_list
56. Shao L-X, Liao C, Davoudian PA, Savalia NK, Jiang Q, Wojtasiewicz C, et al. Psilocybin’s lasting action requires pyramidal cell types and 5-HT2A receptors. Nature. 2025;642:411–420.
    pubmed_reference_list
57. Cameron LP, Tombari RJ, Lu J, Pell AJ, Hurley ZQ, Ehinger Y, et al. A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature. 2021;589:474–9.
    pubmed_reference_list
58. Arias HR, Rudin D, Hines DJ, Contreras A, Gulsevin A, Manetti D, et al. The novel non-hallucinogenic compound DM506 (3-methyl-1,2,3,4,5,6-hexahydroazepino[4,5-b]indole) induces sedative- and anxiolytic-like activity in mice by a mechanism involving 5-HT2A receptor activation. Eur J Pharmacol. 2024;966:176329.
    pubmed_reference_list
59. Kaplan AL, Confair DN, Kim K, Barros-Álvarez X, Rodriguiz RM, Yang Y, et al. Bespoke library docking for 5-HT2A receptor agonists with antidepressant activity. Nature. 2022;610:582–91.
    pubmed_reference_list
60. Qu Y, Chang L, Ma L, Wan X, Hashimoto K. Rapid antidepressant-like effect of non-hallucinogenic psychedelic analog lisuride, but not hallucinogenic psychedelic DOI, in lipopolysaccharide-treated mice. Pharmacol Biochem Behav. 2023;222:173500.
    pubmed_reference_list
61. Pogorelov VM, Rodriguiz RM, Roth BL, Wetsel WC. The G protein biased serotonin 5-HT2A receptor agonist lisuride exerts anti-depressant drug-like activities in mice. Front Mol Biosci. 2023;10:1233743.
    pubmed_reference_list
62. Nakamura K, Ikoma Y, Kimura K, Nakada Y, Kobayashi S, Yamaguchi M, et al. [Effects in animal models of depression of lisuride alone and upon coadministration with antidepressants]. Nihon Yakurigaku Zasshi. 1989;94:81–9.
    pubmed_reference_list
63. Kenakin T. Biased receptor signaling in drug discovery. Pharmacol Rev. 2019;71:267–315.
    pubmed_reference_list
64. Wootten D, Christopoulos A, Marti-Solano M, Babu MM, Sexton PM. Mechanisms of signalling and biased agonism in G protein-coupled receptors. Nat Rev Mol Cell Biol. 2018;19:638–53.
    pubmed_reference_list
65. Kim D, Tokmakova A, Woo J-AA, An SS, Goddard WA, Liggett SB. Selective signal capture from multidimensional GPCR outputs with biased agonists: progress towards novel drug development. Mol Diagn Ther. 2022;26:383–96.
    pubmed_reference_list
66. Raote I, Bhattacharya A, Panicker MM Serotonin 2A (5-HT(2A)) Receptor Function: Ligand-Dependent Mechanisms and Pathways. In: Chattopadhyay A, editor. Serotonin Receptors in Neurobiology. Frontiers in Neuroscience. Boca Raton (FL) 2007.
    pubmed_reference_list
67. López-Giménez JF, González-Maeso J. Hallucinogens and Serotonin 5-HT(2A) receptor-mediated signaling pathways. Curr Top Behav Neurosci. 2018;36:45–73.
    pubmed_reference_list
68. Bennison SA, Blazejewski SM, Smith TH, Toyo-Oka K. Protein kinases: master regulators of neuritogenesis and therapeutic targets for axon regeneration. Cell Mol Life Sci. 2020;77:1511–30.
    pubmed_reference_list
69. Read DE, Gorman AM. Involvement of Akt in neurite outgrowth. Cell Mol Life Sci. 2009;66:2975–84.
    pubmed_reference_list
70. Yang P, Li ZQ, Song L, Yin YQ. Protein kinase C regulates neurite outgrowth in spinal cord neurons. Neurosci Bull. 2010;26:117–25.
    pubmed_reference_list
71. Rodriguiz RM, Nadkarni V, Means CR, Pogorelov VM, Chiu Y-T, Roth BL, et al. LSD-stimulated behaviors in mice require β-arrestin 2 but not β-arrestin 1. Sci Rep. 2021;11:17690.
    pubmed_reference_list
72. Wacker D, Wang S, McCorvy JD, Betz RM, Venkatakrishnan AJ, Levit A, et al. Crystal Structure of an LSD-Bound Human Serotonin Receptor. Cell. 2017;168:377–89.e12.
    pubmed_reference_list
73. Kim K, Che T, Panova O, DiBerto JF, Lyu J, Krumm BE, et al. Structure of a hallucinogen-activated Gq-Coupled 5-HT(2A) serotonin receptor. Cell. 2020;182:1574–88.e19.
    pubmed_reference_list
74. Schmid CL, Raehal KM, Bohn LM. Agonist-directed signaling of the serotonin 2A receptor depends on beta-arrestin-2 interactions in vivo. Proc Natl Acad Sci USA. 2008;105:1079–84.
    pubmed_reference_list
75. Schmid CL, Bohn LM. Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a ß-arrestin2/Src/Akt signaling complex in vivo. J Neurosci. 2010;30:13513–24.
    pubmed_reference_list
76. Wallach J, Cao AB, Calkins MM, Heim AJ, Lanham JK, Bonniwell EM, et al. Identification of 5-HT(2A) receptor signaling pathways associated with psychedelic potential. Nat Commun. 2023;14:8221.
    pubmed_reference_list
77. Carrión-Antolí Á, Mallor-Franco J, Arroyo-Urea S, García-Nafría J Chapter Eight - Structural insights into promiscuous GPCR-G protein coupling. In: Shukla AK, editor. Progress in Molecular Biology and Translational Science. 195: Academic Press; 2023. p. 137-52.
    pubmed_reference_list
78. Masuho I, Kise R, Gainza P, Von Moo E, Li X, Tany R, et al. Rules and mechanisms governing G protein coupling selectivity of GPCRs. Cell Rep. 2023;42:113173.
    pubmed_reference_list
79. Gaitonde SA, Avet C, de la Fuente Revenga M, Blondel-Tepaz E, Shahraki A, Pastor AM, et al. Pharmacological fingerprint of antipsychotic drugs at the serotonin 5-HT(2A) receptor. Mol Psychiatry. 2024;29:2753–64.
    pubmed_reference_list
80. Kossatz E, Diez-Alarcia R, Gaitonde SA, Ramon-Duaso C, Stepniewski TM, Aranda-Garcia D, et al. G protein-specific mechanisms in the serotonin 5-HT(2A) receptor regulate psychosis-related effects and memory deficits. Nat Commun. 2024;15:4307.
    pubmed_reference_list
81. Gurevich VV, Gurevich EV. How and why do GPCRs dimerize?. Trends Pharmacol Sci. 2008;29:234–40.
    pubmed_reference_list
82. Faron-Górecka A, Szlachta M, Kolasa M, Solich J, Górecki A, Kuśmider M, et al. Chapter 10 - Understanding GPCR dimerization. In: Shukla AK, editor. Methods in Cell Biology. 149: Academic Press; 2019. p. 155-78.
    pubmed_reference_list
83. Milligan G. G protein-coupled receptor dimerization: function and ligand pharmacology. Mol Pharmacol. 2004;66:1–7.
    pubmed_reference_list
84. Łukasiewicz S, Polit A, Kędracka-Krok S, Wędzony K, Maćkowiak M, Dziedzicka-Wasylewska M. Hetero-dimerization of serotonin 5-HT2A and dopamine D2 receptors. Biochimica et Biophysica Acta (BBA) - Mol Cell Res. 2010;1803:1347–58.
    pubmed_reference_list
85. Albizu L, Holloway T, González-Maeso J, Sealfon SC. Functional crosstalk and heteromerization of serotonin 5-HT2A and dopamine D2 receptors. Neuropharmacology. 2011;61:770–7.
    pubmed_reference_list
86. Szlachta M, Kuśmider M, Pabian P, Solich J, Kolasa M, Żurawek D, et al. Repeated clozapine increases the level of serotonin 5-HT(1A)R heterodimerization with 5-HT(2A) or dopamine D(2) receptors in the mouse cortex. Front Mol Neurosci. 2018;11:40.
    pubmed_reference_list
87. Galindo L, Moreno E, López-Armenta F, Guinart D, Cuenca-Royo A, Izquierdo-Serra M, et al. Cannabis users show enhanced expression of CB1-5HT2A receptor heteromers in olfactory neuroepithelium cells. Mol Neurobiol. 2018;55:6347–61.
    pubmed_reference_list
88. González-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, López-Giménez JF, et al. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature. 2008;452:93–7.
    pubmed_reference_list
89. Saha S, González-Maeso J. The crosstalk between 5-HT(2A)R and mGluR2 in schizophrenia. Neuropharmacology. 2023;230:109489.
    pubmed_reference_list
90. Moreno JL, Miranda-Azpiazu P, García-Bea A, Younkin J, Cui M, Kozlenkov A, et al. Allosteric signaling through an mGlu2 and 5-HT2A heteromeric receptor complex and its potential contribution to schizophrenia. Sci Signal. 2016;9:ra5.
    pubmed_reference_list
91. González-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, et al. Hallucinogens recruit specific cortical 5-HT2A receptor-mediated signaling pathways to affect behavior. Neuron. 2007;53:439–52.
    pubmed_reference_list
92. Moreno JL, Holloway T, Albizu L, Sealfon SC, González-Maeso J. Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists. Neurosci Lett. 2011;493:76–9.
    pubmed_reference_list
93. Brea J, Castro M, Giraldo J, López-Giménez JF, Padín JF, Quintián F, et al. Evidence for distinct antagonist-revealed functional states of 5-hydroxytryptamine(2A) receptor homodimers. Mol Pharmacol. 2009;75:1380–91.
    pubmed_reference_list
94. Iglesias A, Cimadevila M, Cadavid MI, Loza MI, Brea J. Serotonin-2A homodimers are needed for signalling via both phospholipase A2 and phospholipase C in transfected CHO cells. Eur J Pharmacol. 2017;800:63–9.
    pubmed_reference_list
95. Bockaert J, Roussignol G, Bécamel C, Gavarini S, Joubert L, Dumuis A, et al. GPCR-interacting proteins (GIPs): nature and functions. Biochem Soc Trans. 2004;32:851–5.
    pubmed_reference_list
96. Xia Z, Gray JA, Compton-Toth BA, Roth BL. A direct interaction of PSD-95 with 5-HT2A serotonin receptors regulates receptor trafficking and signal transduction *. J Biol Chem. 2003;278:21901–8.
    pubmed_reference_list
97. Bécamel C, Gavarini S, Chanrion B, Alonso G, Galéotti N, Dumuis A, et al. The serotonin 5-HT2A and 5-HT2C receptors interact with specific sets of PDZ proteins *. J Biol Chem. 2004;279:20257–66.
    pubmed_reference_list
98. Abbas AI, Yadav PN, Yao W-D, Arbuckle MI, Grant SGN, Caron MG, et al. PSD-95 is essential for hallucinogen and atypical antipsychotic drug actions at serotonin receptors. J Neurosci. 2009;29:7124–36.
    pubmed_reference_list
99. Vargas MV, Dunlap LE, Dong C, Carter SJ, Tombari RJ, Jami SA, et al. Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors. Science. 2023;379:700–6.
    pubmed_reference_list
100. Carhart-Harris RL, Leech R, Hellyer PJ, Shanahan M, Feilding A, Tagliazucchi E, et al. The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. Front Hum Neurosci. 2014;8:20.
     pubmed_reference_list
101. Schartner MM, Carhart-Harris RL, Barrett AB, Seth AK, Muthukumaraswamy SD. Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin. Sci Rep. 2017;7:46421.
     pubmed_reference_list
102. Olson DE. Psychoplastogens: a promising class of plasticity-promoting neurotherapeutics. J Exp Neurosci. 2018;12:1179069518800508.
     pubmed_reference_list
103. Flanagan TW, Nichols CD. Psychedelics as anti-inflammatory agents. Int Rev Psychiatry. 2018;30:363–75.
     pubmed_reference_list
104. Flanagan TW, Nichols CD. Psychedelics and anti-inflammatory activity in animal models. Curr Top Behav Neurosci. 2022;56:229–45.
     pubmed_reference_list
105. Fontanilla D, Johannessen M, Hajipour AR, Cozzi NV, Jackson MB, Ruoho AE. The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator. Science. 2009;323:934–7.
     pubmed_reference_list
106. Szabo A, Kovacs A, Frecska E, Rajnavolgyi E. Psychedelic N,N-dimethyltryptamine and 5-methoxy-N,N-dimethyltryptamine modulate innate and adaptive inflammatory responses through the sigma-1 receptor of human monocyte-derived dendritic cells. PLoS ONE. 2014;9:e106533.
     pubmed_reference_list
107. Carhart-Harris RL, Roseman L, Haijen E, Erritzoe D, Watts R, Branchi I, et al. Psychedelics and the essential importance of context. J Psychopharmacol. 2018;32:725–31.
     pubmed_reference_list
108. Robinson ESJ The development of translational tasks for preclinical psychedelic research in psychiatry. Journal of Psychopharmacology. 2025:02698811251365167.
     pubmed_reference_list
109. Kangas BD, Wooldridge LM, Luc OT, Bergman J, Pizzagalli DA. Empirical validation of a touchscreen probabilistic reward task in rats. Transl Psychiatry. 2020;10:285.
     pubmed_reference_list
110. Sarris J, Halman A, Urokohara A, Lehrner M, Perkins D. Artificial intelligence and psychedelic medicine. Ann N Y Acad Sci. 2024;1540:5–12.
     pubmed_reference_list
111. Kim S-H, Yang S, Jung J, Choi J, Kang M, Joo J-Y. Psychedelic drugs in mental disorders: current clinical scope and deep learning-based advanced perspectives. Adv Sci. 2025;12:2413786.
     pubmed_reference_list
112. Aboharb F, Davoudian PA, Shao L-X, Liao C, Rzepka GN, Wojtasiewicz C, et al. Classification of psychedelics and psychoactive drugs based on brain-wide imaging of cellular c-Fos expression. Nat Commun. 2025;16:1590.
     pubmed_reference_list
113. Urbina F, Jones T, Harris JS, Snyder SH, Lane TR, Ekins S. Predicting the hallucinogenic potential of molecules using artificial intelligence. ACS Chem Neurosci. 2024;15:3078–89.
     pubmed_reference_list
114. Pallavicini C, Vilas MG, Villarreal M, Zamberlan F, Muthukumaraswamy S, Nutt D, et al. Spectral signatures of serotonergic psychedelics and glutamatergic dissociatives. Neuroimage. 2019;200:281–91.
     pubmed_reference_list
115. Brown N, Fiscato M, Segler MHS, Vaucher AC. GuacaMol: benchmarking models for de novo molecular design. J Chem Inf Model. 2019;59:1096–108.
     pubmed_reference_list
116. Kas MJH, Penninx BWJH, Knudsen GM, Cuthbert B, Falkai P, Sachs GS, et al. Precision psychiatry roadmap: towards a biology-informed framework for mental disorders. Mol Psychiatry. 2025;30:3846–55.
     pubmed_reference_list

Dokładne dopasowania identyfikatorów

Nie znaleziono dopasowań w tej grupie.

Kandydaci do ręcznej kontroli

• Esketamine in treatment-resistant depression with and without comorbid borderline personality disorder: A real-world longitudinal study of suicidal ideation and self-harm. · src_42019344 · PROBABLE_MATCH · rok 2026
• Intranasal esketamine in treatment-resistant depression with and without comorbid borderline personality disorder: A multicenter real-world longitudinal study. · src_42322927 · PROBABLE_MATCH · rok 2026
• Suicidal ideation covaries with depressive severity during six-month real-world esketamine treatment in a cohort enriched for borderline personality disorder. · src_42624219 · PROBABLE_MATCH · rok 2026

Konflikty

Nie znaleziono dopasowań w tej grupie.

Podobieństwo nie scala rekordów i nie potwierdza tożsamości publikacji.

Zakres: jawne relacje claims[].source_ids[] powiązane z publikacją.